Bradykinin B-2 receptor involvement in rabbit and murine models of septic shock

被引:15
|
作者
Feletou, M
Jamonneau, I
Germain, M
Thurieau, C
Fauchere, JL
Villa, P
Ghezzi, P
Canet, E
机构
[1] INST RECH SERVIER, DEPT CHIM PEPTIDES, F-92150 SURESNES, FRANCE
[2] INST PHARMACOL RES MARIO NEGRI, MILAN, ITALY
[3] CTR CYTOPHARMACOL, CNR, MILAN, ITALY
[4] CTR CYTOPHARMACOL, DEPT PHARMACOL, MILAN, ITALY
关键词
HOE; 140; bradykinin B-2 receptor; sepsis; endotoxin; shock;
D O I
10.1097/00005344-199604000-00008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The purpose of our work was to evaluate the role of bradykinin B-2 receptors in the early phase (first 3 h) of bacterial lipopolysaccharide (LPS)-induced shock in anesthetized and mechanically ventilated rabbits and to determine if HOE 140, a specific, potent, and long-acting bradykinin B-2-receptor antagonist, could improve survival in two murine models of septic shock. In rabbits, LPS injection induced rapid hypotension associated with metabolic acidosis. Three hours after the injection of LPS, we observed leukopenia, thrombocytopenia, and a moderate increase in arterial blood cyclic GMP. The injection-of HOE 140 [1.7-mu mol/kg bolus intravenously (i.v.) 20 min before LPS] inhibited the decrease in blood pressure, but did not influence any of the other parameters studied. Mice were subjected to intraperitoneal (i.p.) injection of LPS, which induced almost 100% mortality in the 4 days after the injection. Pretreatment with HOE 140 (1 mg/kg i.p.) 30 min before the LPS injection and 4, 8, and 24 h afterward the injection did not improve survival at any given time during the 4 days of the study. Cecal ligation and puncture in mice induced a mortality rate >90% in less than or equal to 10 days. HOE 140 (1 mg/kg i.v.) given 30 min before cecal ligation did not significantly improve the survival rate. In contrast with previous reports, in the present study in a rabbit model of endotoxic shock (early phase) and in two murine models of septic shock, the involvement of bradykinin B-2 receptors appeared to be minimal.
引用
收藏
页码:500 / 507
页数:8
相关论文
共 50 条
  • [1] Cloning and pharmacological characterization of the rabbit bradykinin B-2 receptor
    Bachvarov, DR
    SaintJacques, E
    Larrivee, JF
    Levesque, L
    Rioux, F
    Drapeau, G
    Marceau, F
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1995, 275 (03): : 1623 - 1630
  • [2] Central B-2 receptor involvement in the antinociceptive effect of bradykinin in rats
    Pela, IR
    Rosa, AL
    Silva, CAA
    HuidobroToro, JP
    BRITISH JOURNAL OF PHARMACOLOGY, 1996, 118 (06) : 1488 - 1492
  • [3] BRADYKININ RECEPTOR TYPES AND B-2 SUBTYPES
    REGOLI, D
    GOBEIL, F
    NGUYEN, QT
    JUKIC, D
    SEOANE, PR
    SALVINO, JM
    SAWUTZ, DG
    LIFE SCIENCES, 1994, 55 (10) : 735 - 749
  • [4] Simulations on the activation of the bradykinin B-2 receptor
    Doughty, SW
    Reynolds, CA
    BIOCHEMICAL SOCIETY TRANSACTIONS, 1996, 24 (01) : 259 - 263
  • [5] SYNTHESIS OF NONPEPTIDE BRADYKININ B-2 RECEPTOR ANTAGONISTS
    DOUTY, BD
    SALVINO, JM
    SEOANE, PR
    DOLLE, RE
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1995, 5 (04) : 363 - 366
  • [7] CHARACTERIZATION OF A SENSITIVE BRADYKININ B-2 PREPARATION IN THE RABBIT SCIATIC VEIN
    KEIR, RF
    STUART, EF
    BRITISH JOURNAL OF PHARMACOLOGY, 1995, 115 : P141 - P141
  • [8] GENERATION OF HOMOZYGOUS B-2 BRADYKININ RECEPTOR KNOCKOUT MICE
    BORKOWSKI, JA
    TRUMBAUER, M
    CHEN, H
    HESS, JF
    FASEB JOURNAL, 1995, 9 (04): : A668 - A668
  • [9] Nonpeptide mimic of Bradykinin with long-acting properties at the Bradykinin B-2 receptor
    Aramori, I
    Zenkoh, J
    Morikawa, N
    Asano, M
    Hatori, C
    Sawai, H
    Kayakiri, H
    Satoh, S
    Inoue, T
    Abe, Y
    Sawada, Y
    Mizutani, T
    Inamura, N
    Nakahara, K
    Kojo, H
    Oku, T
    Notsu, Y
    MOLECULAR PHARMACOLOGY, 1997, 52 (01) : 16 - 20
  • [10] THE INVOLVEMENT OF BRADYKININ B-1 AND B-2 RECEPTOR MECHANISMS IN CYTOKINE-INDUCED MECHANICAL HYPERALGESIA IN THE RAT
    DAVIS, AJ
    PERKINS, MN
    BRITISH JOURNAL OF PHARMACOLOGY, 1994, 113 (01) : 63 - 68